R 715

R 715 is a synthetic peptide compound designed as an antagonist of bradykinin B2 receptors, widely recognized in biochemical research for its role in modulating the kallikrein-kinin system. As a peptide, it features a specific sequence that enables high-affinity binding to B2 receptors, thereby inhibiting the physiological actions of bradykinin. The compound is valued for its selectivity and potency, making it a critical tool for dissecting bradykinin-mediated pathways in various experimental models. Researchers utilize R 715 to elucidate the complex signaling mechanisms underlying inflammation, vascular tone regulation, and pain perception, contributing to a deeper understanding of peptide-receptor interactions in physiological and pathophysiological contexts.

Receptor pharmacology: R 715 is extensively applied in studies investigating the pharmacological properties of bradykinin B2 receptors. By selectively blocking B2 receptor activation, the compound allows researchers to characterize receptor binding kinetics, signal transduction pathways, and downstream biological effects in both cellular and tissue-based assays. This targeted approach aids in distinguishing the specific contributions of B2 receptors from those of other kinin receptors, thereby refining the understanding of receptor subtype functionality.

Inflammation research: The peptide serves as a valuable tool in probing the molecular mechanisms of inflammation, particularly in models where bradykinin is implicated as a key mediator. By inhibiting B2 receptor signaling, R 715 enables the assessment of bradykinin's role in promoting vascular permeability, leukocyte recruitment, and cytokine production. Such studies facilitate the identification of critical nodes in inflammatory cascades and support the development of strategies for modulating inflammatory responses at the molecular level.

Vascular biology: In the context of vascular research, R 715 is used to investigate the regulation of endothelial function and vascular tone. Bradykinin is known to induce vasodilation through B2 receptor-mediated nitric oxide and prostaglandin release. By antagonizing these receptors, the peptide helps delineate the specific pathways involved in endothelium-dependent relaxation and provides insight into the physiological regulation of blood flow and vascular resistance.

Pain signaling studies: The compound is instrumental in exploring the role of bradykinin B2 receptors in nociceptive pathways. Experimental models utilizing R 715 allow for the dissection of bradykinin's contribution to pain perception, hyperalgesia, and neurogenic inflammation. These studies are essential for mapping the molecular underpinnings of pain signaling and for identifying potential targets for analgesic intervention in preclinical research settings.

Peptide-receptor interaction analysis: R 715 is also employed in structural and functional studies aimed at understanding peptide-receptor interactions at the molecular level. Its defined sequence and receptor specificity make it suitable for use in binding assays, mutagenesis experiments, and computational modeling. These applications provide detailed insights into the determinants of ligand-receptor affinity and selectivity, supporting the rational design of novel peptide-based modulators for research purposes.

1. An Isolated TCR αβ Restricted by HLA-A* 02: 01/CT37 Peptide Redirecting CD8+ T Cells to Kill and Secrete IFN-γ in Response to Lung Adenocarcinoma Cell Lines

2. Cationic cell-penetrating peptides are potent furin inhibitors

3. Immune responses to peptides containing homocitrulline or citrulline in the DR4-transgenic mouse model of rheumatoid arthritis

4. Investigating Potential Interactions Between Neurohypophyseal Peptides, their Drug Analogs, and Coagulation Factor VIII

5. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation